SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 11.96 |
| Enterprise Value ($M) | -86.76 |
| Book Value ($M) | -101.08 |
| Book Value / Share | -97.75 |
| Price / Book | -0.12 |
| NCAV ($M) | -113.60 |
| NCAV / Share | -109.85 |
| Price / NCAV | -0.11 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -5.90 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.52 |
| Current Ratio | 0.52 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 111.21 |
| Assets | 123.73 |
| Liabilities | 224.81 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 1.92 |
| Operating Income | -23.44 |
| Net Income | -31.54 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -30.68 |
| Cash from Investing | -0.13 |
| Cash from Financing | 25.04 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Allostery Investments LP | 7.60 | ||
| 13G | Emerald Bioventures, LLC | 5.60 | ||
| 13G | Deep Track Capital, LP | 9.99 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 0.00 | -100.00 | |
| 13G/A | Nantahala Capital Management, LLC | 4.90 | -93.57 | |
| 13G/A | Great Point Partners Llc | 0.26 | ||
| 13G/A | Point72 Asset Management, L.P. | 0.30 | -99.96 | |
| 13G/A | Caissa Capital Management ltd. | 0.00 | -100.00 | |
| 13D/A | Armistice Capital, Llc | 4.99 | -86.97 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 423 | 6,659 | 6.35 | |
| 476 | 4,004 | 11.89 | |
| 1,354 | 13,119 | 10.32 | |
| 420 | 4,182 | 10.04 | |
| 216 | 5,587 | 3.87 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ATOS – Atossa Therapeutics, Inc. | ATXI – Avenue Therapeutics, Inc. |
| ATYR – aTyr Pharma, Inc. | AWH – Aspira Women's Health Inc. |
| AYTU – Aytu BioPharma, Inc. |
Financial data and stock pages provided by
Fintel.io